Most digital health companies fail at adoption, not at innovation. After years on both sides of the table, building health tech products and running the delivery systems that had to decide whether to sign the contract, I've noticed something. The companies that actually scale share a recognizable pattern. Not one or two characteristics. A pattern.
I want to describe what that pattern looks like from the inside out, because if you are building in this space, evaluating investments, or running a health system that is deciding what to actually commit to, this is the diagnostic framework I use. It is not theoretical. It came from watching the graveyard fill up.
Every major health system in North America has one.
There's no sign. No official record. No executive who wants to bring it up at the annual innovation conference. But it exists in every portfolio, every leader's institutional memory, and every physician's mind who was asked to "try this for 90 days."
I call it the Digital Health Graveyard: the collection of proof-of-concept projects that showed genuine improvement, that helped patients, that clinicians actually liked, and that still quietly disappeared by month six. The most disorienting thing about the graveyard is that almost everything buried there actually worked. The science was sound. The pilot data was real.
It did not fail because of bad technology. It failed because there is a gap between a technology that can be deployed and a health system that has the capacity to actually absorb it. That is a different problem. And it requires a different solution.
So how do you tell the difference, in advance, between a company headed for the graveyard and one that is going to stick? Here is what I look for.
Not "it improves workflow." Not "clinicians love it." They can tell you: it adds 1.5 clicks to the nursing handoff, removes three documentation fields, and saves approximately four minutes per patient encounter in primary care. That specificity is not accidental. The team spent real time in real clinical environments. They did not user-test in a demo setup. They watched actual clinicians under actual time pressure.
The practical test: the average primary care physician has 12 minutes per patient encounter. That includes the history, the exam, the clinical decision, and the documentation. 12 minutes. The question for your product is not "does this work?" The question is: does this fit inside 8 minutes? And does it help, or does it add friction? If you cannot answer that precisely, with evidence from a clinician who used it in their real workflow, not a demo, you probably have a very good demo. A great demo is not the same thing as a scalable product.
Most health tech teams treat reimbursement as a late-stage compliance issue: something you figure out after the product works, after the pilot succeeds, after the enterprise conversation starts. By then, it is too late and expensive to fix.
The companies that scale can tell you, from Year 2 forward, which billing pathway governs their product, which payers are going to push back, what evidence they'll need to influence coverage policy, and what the bridge revenue model is if reimbursement takes longer than expected. They did not hire a health economist in Year 4. They built it into the product spec before the first line of code. In the US, that means CPT codes, Medicare coverage, and commercial payer policy. In Canada, it means understanding provincial-level coverage decisions at the Ministry of Health. The sequence matters. Getting it backwards is expensive and usually fatal.
A peer-reviewed publication will not make a health system sign a contract. I know that is uncomfortable if you spent two years designing the study.
What makes a CFO, VP of Operations, or system CMO sign is evidence that directly answers the questions they are already accountable for. Does this reduce cost per episode? Does this reduce readmission rates? Does this improve a metric that shows up on their scorecard? The companies that scale design their clinical studies to answer those questions, not to satisfy journal reviewers. That is not anti-science. It is applied science. The distinction between "this demonstrates efficacy" and "this demonstrates operational value" is the difference between a good pilot and a signed contract.
"A great pilot, by itself, is not a sale. It is a delayed no, with data as an appendix. The health system has learned something. The startup has 90 days of data and a polite promise. Those are not equivalent positions."
In a health system, the person who writes the check is rarely the physician who champions your product in committee meetings. It is the CFO. It is the VP of Strategy. It is the system CMO looking at next year's capital budget. The companies that scale knew who that person was before they built their first slide deck. They know that person's budget cycle, their top three accountability metrics, and what it takes to get a yes from them specifically.
The clinical champion matters enormously. They open doors, navigate internal politics, advocate in meetings, and help you understand the workflow in ways no survey can capture. But the clinical champion is not the one who triggers a yes. The economic buyer does. And they are not persuaded by the same things. If your entire go-to-market is clinical champion relationship, you are building on one very fragile pillar.
This is the one founders get wrong most consistently, and it is the hardest to see from inside the company.
The technical question is straightforward: can your architecture handle 10,000 users? The organizational question is harder: can the health system you are selling to actually implement this technology with their existing staff, their existing processes, and their existing change management infrastructure? Health systems do not have infinite implementation bandwidth. They are running dozens of technology initiatives simultaneously. Your product will go into a queue, and if your implementation requires six months of staff training, a dedicated project manager, and weekly check-ins with your customer success team, you are not building for the system that exists. You are building for a system you imagined.
The companies that scale treat low implementation burden as a core design principle from the beginning. They make it easy to start. Then they make it even easier to stay. Organizational scalability is not an afterthought. It is a spec.
I was trained as a surgeon. Surgeons do not write prescriptions before they have done a diagnosis. You gather information, you look for patterns, you resist the pull toward a satisfying answer before you have the evidence.
The innovations that actually scale are built by founders who ran the diagnostic first. They diagnosed the workflow constraint. They diagnosed the reimbursement landscape. They diagnosed the organizational capacity to adopt what they were building. And then they built a product that fit the diagnosis.
That is not a counsel of despair. It is precision. Healthcare is hard to change. It is absolutely worth changing. The patients that these systems serve every day deserve innovations that do not just win a pitch competition and then disappear into the graveyard. They deserve technologies that actually get deployed, at scale, in the systems that exist.
None of these five signals are revolutionary. None of them are counterintuitive in isolation. All of them are systematically under-executed by early-stage companies, because the urgency of building a product crowds out the discipline of understanding the system that product has to survive in.
The companies that scale figure this out early. That is the only material difference.
If you are building in health tech, evaluating a deal, or running a delivery system trying to figure out what to actually commit to, let's talk.
Schedule a conversation